A Drug With Efficacy Superior to That of Memantine Would Earn up to a 50% Patient Share in the Moderate-to-Severe Alzheimer's Disease Drug Market

Thursday, March 6, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

WALTHAM, Mass., March 6 Decision Resources, one of theworld's leading research and advisory firms focusing on pharmaceutical andhealthcare issues, finds that a drug with efficacy superior to that of salesleader memantine would earn up to a 50% patient share in the market to treatmoderate-to-severe Alzheimer's disease. The currently available brandedversions of memantine are Forest Laboratories' Namenda, Lundbeck's Ebixa andMerz/Grupo Grunenthal's Axura/Akatinol.

The new report entitled Alzheimer's Disease (Moderate to Severe):Incremental Improvements in Efficacy Can Lead to Large Commercial Opportunityfinds that a symptomatic therapy with efficacy greater than that of memantine,as measured by the Severe Impairment Battery score at 28 weeks, would earn apatient share of 40-50% in the moderate-to-severe Alzheimer's disease market,according to surveyed neurologists. In addition to replacing memantine in mostcases, physicians believe that, if such a therapy were launched, it wouldthreaten a significant percentage of prescriptions of donepezil(Eisai/Pfizer's Aricept and Bracco's Memac) and the memantine/donepezilcombination.

The report also finds that a therapy's effect on cognitive decline is theattribute that most influences the prescribing decisions of neurologists intreating moderate-to-severe Alzheimer's disease. Clinical data and interviewedexperts indicate that Myriad Genetics' Flurizan, Elan/Wyeth's bapineuzumab,Medivation's Dimebon and Eli Lilly's LY-450139 all have advantages over sales-leading memantine on this attribute.

"Some agents, including Flurizan and bapineuzumab, will be used incombination with existing drugs rather than replacing them," said NitashaManchanda, Ph.D., analyst at Decision Resources. "Approximately one-third ofthe neurologists we surveyed said they will use Flurizan adjunctively andnearly half of the neurologists surveyed will use bapineuzumab as an adjunctto current therapies."

About the Report

Alzheimer's Disease (Moderate to Severe): Incremental Improvements inEfficacy Can Lead to Large Commercial Opportunity is a DecisionBase 2008report from Decision Resources. DecisionBase 2008 combines market forecastswith clinical and commercial end points to assess market share projections in35 indications. These outputs are driven by quantitative and qualitativeprimary research. DecisionBase 2008 provides detailed market share, patientshare, and price-per-day projections for emerging drugs in development. Themarket share projections are based on prescriber surveys that comparephysicians' expectations of a potential target product profile with anemerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members ofthe media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (www.decisionresources.com) is a world leader inmarket research publications, advisory services, and consulting designed tohelp clients shape strategy, allocate resources, and master their chosenmarkets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com

SOURCE Decision Resources

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store